DK0792154T3 - Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna) - Google Patents

Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna)

Info

Publication number: DK0792154T3
Authority: DK; Denmark
Prior art keywords: dithio; bis; cisplatin; dimesna; ethanesulfonate
Prior art date: 1994-11-14

Application number

DK95939282T

Other languages

Danish (da)

English (en)

Inventor

Peddaiahgari Seetharamulu

Frederick Herman Hausheer

Kochat Haridas

Dhanabalan Murali

Dasharatha Gauravaram Reddy

Original Assignee

Bionumerik Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-14

Filing date

1995-11-14

Publication date

2003-08-04

1995-11-14 Application filed by Bionumerik Pharmaceuticals Inc filed Critical Bionumerik Pharmaceuticals Inc

2003-08-04 Application granted granted Critical

2003-08-04 Publication of DK0792154T3 publication Critical patent/DK0792154T3/da

Links

BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title abstract 2
229960004316 cisplatin Drugs 0.000 title abstract 2
229950009278 dimesna Drugs 0.000 title 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 abstract 2
238000009472 formulation Methods 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
231100000268 induced nephrotoxicity Toxicity 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Toxicology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

DK95939282T 1994-11-14 1995-11-14 Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna) DK0792154T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/338,379 US5789000A (en)	1994-11-14	1994-11-14	Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
PCT/EP1995/004490 WO1996014852A1 (en)	1994-11-14	1995-11-14	Composition of cisplatin in combination with 2,2'-dithio-bis(ethanesulfonate) (dimesna)

Publications (1)

Publication Number	Publication Date
DK0792154T3 true DK0792154T3 (da)	2003-08-04

Family

ID=23324592

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95939282T DK0792154T3 (da)	1994-11-14	1995-11-14	Sammensætning af cisplatin i kombination med 2,2'-dithio-bis(ethansulfonat) (dimesna)

Country Status (13)

Country	Link
US (5)	US5789000A (de)
EP (1)	EP0792154B1 (de)
JP (3)	JP4171526B2 (de)
KR (1)	KR100411380B1 (de)
CN (2)	CN101987111A (de)
AT (1)	ATE237337T1 (de)
AU (1)	AU706181B2 (de)
CA (1)	CA2202170C (de)
DE (1)	DE69530412T2 (de)
DK (1)	DK0792154T3 (de)
ES (1)	ES2191717T3 (de)
PT (1)	PT792154E (de)
WO (1)	WO1996014852A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
US6025488A (en) *	1994-11-14	2000-02-15	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) *	1994-11-14	1998-08-04	Bionumerik Pharmaceuticals, Inc.	Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US6037336A (en) *	1996-09-23	2000-03-14	Bionumerik Pharmaceuticals, Inc.	Reducing toxic effects of carboplatin using dithioethers
DK0957920T3 (da) *	1996-09-23	2002-04-02	Bionumerik Pharmaceuticals Inc	Reduktion af carboplatins toksiske effekt under anvendelse af dithioethere
US20070142267A1 (en) *	1998-11-23	2007-06-21	Novelos Therapeutics, Inc.	Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) *	1998-11-23	2000-01-20	Закрытое акционерное общество "ВАМ"	Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US6312734B1 (en) *	1998-11-23	2001-11-06	Novelos Therapeutics, Inc.	Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6197831B1 (en) *	1999-02-09	2001-03-06	Bionumerik Pharmaceuticals, Inc.	Method of treating septic shock
US6034126A (en) *	1999-05-24	2000-03-07	Bionumerik Pharmaceuticals, Inc.	Method for treating glycol poisoning
JP4776843B2 (ja)	1999-10-01	2011-09-21	イムノゲンインコーポレーティッド	免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US6156350A (en) *	1999-12-02	2000-12-05	Corazon Technologies, Inc.	Methods and kits for use in preventing restenosis
KR20030014208A (ko)	2000-04-26	2003-02-15	오레곤 헬스 사이언시즈 유니버시티	티올계 화학보호제 화합물의 투여
GB0011903D0 (en) *	2000-05-18	2000-07-05	Astrazeneca Ab	Combination chemotherapy
JP2004512381A (ja) *	2000-11-02	2004-04-22	スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ	Ｈｓｐ９０インヒビターの使用により細胞毒性剤の効力を増強させる方法
US6540733B2 (en) *	2000-12-29	2003-04-01	Corazon Technologies, Inc.	Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
WO2002056755A2 (en) *	2001-01-19	2002-07-25	Bionumerik Pharmaceuticals, Inc.	Method for treating cancer
CA2441228A1 (en) *	2001-03-23	2002-10-03	Aphton Corporation	Combination treatment of pancreatic cancer
US20090191232A1 (en) *	2001-05-04	2009-07-30	Gevas Philip C	Combination therapy for the treatment of tumors
JP2004536835A (ja) *	2001-07-09	2004-12-09	アフトンコーポレーション	肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
US6352979B1 (en) *	2001-08-20	2002-03-05	Lucinda Lizcano	Method of treating snakebite and complications resulting therefrom
CN101062053A (zh) *	2001-09-24	2007-10-31	托斯克公司	减低毒性的顺铂制剂及其使用方法
US7176192B2 (en) *	2001-10-26	2007-02-13	Bionumerik Pharmaceuticals, Inc.	Method for treating patients for radiation exposure
US6596320B1 (en) *	2002-01-11	2003-07-22	Bionumerik Pharmaceuticals, Inc.	Method for treating cancer having greater efficacy and reduced adverse effects
US8722331B2 (en) *	2002-03-28	2014-05-13	University Of Toledo	Method for selecting a treatment for non-small cell lung cancer using gene expression profiles
US8710095B2 (en) *	2002-04-30	2014-04-29	Bionumerik Pharmaceuticals, Inc.	Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20040014730A1 (en) *	2002-07-10	2004-01-22	Frederick Hausheer	Formulations and methods of reducing toxicity of anti-infective agents
AU2002360747B2 (en) *	2002-12-21	2008-07-03	Bionumerik Pharmaceuticals, Inc.	Method of treating patients exposed to toxic chemical agents
WO2004094409A1 (en)	2003-03-27	2004-11-04	Lankenau Institute For Medical Research	Novel ido inhibitors and methods of use
US20060020119A1 (en) *	2004-03-29	2006-01-26	Stephen Grimes	Monoclonal antibodies to gastrin hormone
AU2004299131B2 (en) *	2003-12-17	2010-05-13	Bionumerik Pharmaceuticals, Inc.	Process for synthesizing disulfides
US20050256055A1 (en) *	2004-05-12	2005-11-17	Hausheer Frederick H	Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US20090111735A1 (en) *	2004-05-12	2009-04-30	Bionumerik Pharmaceuticals, Inc.	Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US7282602B2 (en) *	2004-09-21	2007-10-16	Bionumerik Pharmaceuticals, Inc.	Medicinal disulfide salts
US7235589B2 (en)	2004-09-21	2007-06-26	Bio Numerik Pharmaceuticals, Inc.	Method of treating patients undergoing kidney dialysis
US20060063742A1 (en) *	2004-09-21	2006-03-23	Hausheer Frederick H	Method of treatment for or protection against lymphedema
EP2567974A3 (de)	2004-09-22	2013-05-22	Cancer Advances, Inc.,	Monoklonale Antikörper gegen Progastrin
CN100443081C (zh) *	2005-04-05	2008-12-17	吴一心	木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
WO2007065167A1 (en) *	2005-12-02	2007-06-07	The Johns Hopkins University	Use of high-dose oxazaphosphorine drugs for treating immune disorders
WO2007070599A2 (en) *	2005-12-13	2007-06-21	Bionumerik Pharmaceuticals, Inc.	Chemoprotective methods and compositions
EP2004175A4 (de) *	2006-03-16	2010-12-15	Bionumerik Pharmaceuticals Inc	Verbindungen und formulierungen zur verstärkung der wirkung gegen krebs und verfahren zu deren verwendung
WO2008034076A2 (en)	2006-09-15	2008-03-20	The Johns Hopkins University	Cyclophosphamide in combination with immune therapeutics
WO2008034074A2 (en)	2006-09-15	2008-03-20	The Johns Hopkins University	Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034071A2 (en)	2006-09-15	2008-03-20	The Johns Hopkins University	Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008097658A1 (en) *	2007-02-09	2008-08-14	Poniard Pharmaceuticals, Inc.	Encapsulated picoplatin
TW200916094A (en) *	2007-06-27	2009-04-16	Poniard Pharmaceuticals Inc	Stabilized picoplatin dosage form
TW200920347A (en) *	2007-07-16	2009-05-16	Poniard Pharmaceuticals Inc	Oral formulations for picoplatin
US8765368B2 (en) *	2007-09-17	2014-07-01	The University Of Toledo	Cancer risk biomarker
US9026372B2 (en) *	2007-11-21	2015-05-05	Accentia Biopharmaceuticals, Inc.	Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (en) *	2007-11-21	2009-05-28	Accentia Biopharmaceuticals, Inc.	Methods for providing a system of care for an oxazaphosphorine drug regimen
AU2009210654A1 (en) *	2008-02-08	2009-08-13	Poniard Pharmaceuticals, Inc.	Use of picoplatin and bevacizumab to treat colorectal cancer
ES2476602T3 (es)	2008-03-14	2014-07-15	Bionumerik Pharmaceuticals, Inc.	Composiciones y métodos quimioprotectores
US9320760B2 (en) *	2008-03-14	2016-04-26	Bionumerik Pharmaceuticals, Inc.	Compositions and methods of use of compounds to increase cancer patient survival time
WO2009113989A1 (en)	2008-03-14	2009-09-17	Bionumerik Pharmaceuticals, Inc.	Compositions and methods of use of compounds to increase cancer patient survival time
DK2249825T3 (en) *	2008-03-14	2016-01-11	Bionumerik Pharmaceuticals Inc	Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
US20110064828A1 (en) *	2009-09-11	2011-03-17	Novelos Therapeutics, Incorporated	Treatment of metastatic tumors and other conditions
TWI438009B (zh) *	2010-02-19	2014-05-21	Teikoku Pharma Usa Inc	紫杉烷前－乳劑調配物及其製造與使用之方法
JP5824511B2 (ja)	2010-05-03	2015-11-25	テイコクファーマユーエスエーインコーポレーテッド	非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
CN115778934A (zh)	2012-01-20	2023-03-14	德玛公司	经取代的己糖醇类用于治疗恶性肿瘤的用途
IN2015DN01369A (de) *	2012-07-19	2015-07-03	Relypsa Inc
JO3685B1 (ar)	2012-10-01	2020-08-27	Teikoku Pharma Usa Inc	صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US12150978B2 (en)	2017-06-15	2024-11-26	Cancer Advances Inc.	Compositions and methods for preventing tumors and cancer
IL271427B2 (en)	2017-06-15	2025-08-01	Cancer Advances Inc	Compositions and methods for inducing humoral and cellular immunities against tumors and cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2806866C3 (de) *	1978-02-17	1981-02-12	Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld	Verwendung von Salzen von Dithiodialkansulfonsäuren
US4310515A (en) *	1978-05-30	1982-01-12	Bristol-Myers Company	Pharmaceutical compositions of cisplatin
ES2040394T3 (es) *	1988-03-19	1993-10-16	Asta Medica Aktiengesellschaft	Procedimiento para preparar un material liofilizado de ifosfamida y mesna.
US5227373A (en) *	1991-10-23	1993-07-13	Bristol-Myers Squibb Co.	Lyophilized ifosfamide compositions
JP3954115B2 (ja) *	1992-07-28	2007-08-08	アストラゼネカ・アクチエボラーグ	注射剤および注射剤キット
US5789000A (en) *	1994-11-14	1998-08-04	Bionumerik Pharmaceuticals, Inc.	Sterile aqueous parenteral formulations of cis-diammine dichloro platinum

1994
- 1994-11-14 US US08/338,379 patent/US5789000A/en not_active Expired - Lifetime
1995
- 1995-11-03 US US08/553,005 patent/US5902610A/en not_active Expired - Lifetime
- 1995-11-14 JP JP51574596A patent/JP4171526B2/ja not_active Expired - Fee Related
- 1995-11-14 CA CA002202170A patent/CA2202170C/en not_active Expired - Lifetime
- 1995-11-14 KR KR1019970703171A patent/KR100411380B1/ko not_active Expired - Lifetime
- 1995-11-14 ES ES95939282T patent/ES2191717T3/es not_active Expired - Lifetime
- 1995-11-14 DE DE69530412T patent/DE69530412T2/de not_active Expired - Lifetime
- 1995-11-14 EP EP95939282A patent/EP0792154B1/de not_active Expired - Lifetime
- 1995-11-14 WO PCT/EP1995/004490 patent/WO1996014852A1/en not_active Ceased
- 1995-11-14 DK DK95939282T patent/DK0792154T3/da active
- 1995-11-14 AU AU41168/96A patent/AU706181B2/en not_active Expired
- 1995-11-14 CN CN2010102328968A patent/CN101987111A/zh active Pending
- 1995-11-14 PT PT95939282T patent/PT792154E/pt unknown
- 1995-11-14 CN CN951962310A patent/CN1165483B/zh not_active Expired - Lifetime
- 1995-11-14 AT AT95939282T patent/ATE237337T1/de active
1997
- 1997-04-18 US US08/844,544 patent/US5866617A/en not_active Expired - Lifetime
- 1997-04-30 US US08/848,361 patent/US5866615A/en not_active Expired - Lifetime
- 1997-06-18 US US08/878,244 patent/US5866169A/en not_active Expired - Lifetime
2008
- 2008-02-28 JP JP2008047977A patent/JP2008133304A/ja active Pending
2012
- 2012-08-02 JP JP2012172119A patent/JP2012211198A/ja active Pending

Also Published As

Publication number	Publication date
JPH10509143A (ja)	1998-09-08
EP0792154A1 (de)	1997-09-03
DE69530412D1 (de)	2003-05-22
PT792154E (pt)	2003-09-30
ATE237337T1 (de)	2003-05-15
CN1165483A (zh)	1997-11-19
US5789000A (en)	1998-08-04
JP2008133304A (ja)	2008-06-12
JP2012211198A (ja)	2012-11-01
KR970706830A (ko)	1997-12-01
CN1165483B (zh)	2012-09-05
AU4116896A (en)	1996-06-06
KR100411380B1 (ko)	2004-04-30
EP0792154B1 (de)	2003-04-16
ES2191717T3 (es)	2003-09-16
MX9703460A (es)	1997-07-31
WO1996014852A1 (en)	1996-05-23
US5866615A (en)	1999-02-02
CN101987111A (zh)	2011-03-23
AU706181B2 (en)	1999-06-10
US5866169A (en)	1999-02-02
US5866617A (en)	1999-02-02
CA2202170C (en)	2007-04-10
CA2202170A1 (en)	1996-05-23
JP4171526B2 (ja)	2008-10-22
US5902610A (en)	1999-05-11
DE69530412T2 (de)	2003-10-30

Publication	Publication Date	Title
DE69530412D1 (de)	2003-05-22	Zusammensetzung aus cisplatin in kombination mit 2,2'-dithio-bis(ethansulfonat)(dimesna)
TR200003333T2 (tr)	2001-02-21	Ensülin direngenliği ve hiperglisemi tedavisinde yararlı benzotiyofenler
PT1025845E (pt)	2003-03-31	Terapia com hidromorfona
ATE69951T1 (de)	1991-12-15	Cancerostatisches mittel.
AU4484989A (en)	1990-06-12	Water soluble 1,2-diaminocyclohexane platinum (iv) complexes as antitumor agents
GR3003068T3 (en)	1993-02-17	(2,2-bis(aminomethyl)-1,3-propanediol-n,n')platinum complexes
IT1230145B (it)	1991-10-14	Complessi di rutenio (iii) come agenti antineoplastici.
DE69510545D1 (de)	1999-08-05	Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
DE69940551D1 (de)	2009-04-23	Mercaptane und disulfide
ES511753A0 (es)	1983-06-01	Un procedimiento para la preparacion de derivados de sucrosa'4-halo-sustituidos.
ATE63316T1 (de)	1991-05-15	Verwendung von n, n'-bis-l-aminosaeure-lcystinpeptiden in aminosaeure-praeparaten fuer orale und parenterale ernaehrung.
EP0237829A3 (en)	1988-01-07	Tetrahydro-3,4-furandiamine-n-n'-platinum complexes
TR199802200A2 (xx)	1999-05-21	S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
TR199900153T2 (xx)	1999-04-21	H�cre �o�almas�n� �nlemek i�in ikame edilmi� bisindolilmaleimitler.
DK1100824T3 (da)	2011-06-20	Forbindelser med væksthormonfrigivende egenskaber
GB9420747D0 (en)	1994-11-30	1,5 benzodiazepine derivatives
DK0957920T3 (da)	2002-04-02	Reduktion af carboplatins toksiske effekt under anvendelse af dithioethere
ATE470671T1 (de)	2010-06-15	Verbindungen mit wachstumshormon-freisetzender eigenschaft
EP0118565A4 (de)	1985-04-03	1,4-methano-2-benzazepin-abkömmlinge.
ATE232723T1 (de)	2003-03-15	Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen
TR199701605A2 (xx)	1998-07-21	S�lfonamid-substit�e edilmi� bile�ikler
DE69807200D1 (de)	2002-09-19	Inklusionskomplexe in waessriger loesung
DE69905144D1 (de)	2003-03-06	N,N'-Diacylthiocystine
NO20012169D0 (no)	2001-05-02	Forbindelser med veksthormonfrigjörende egenskaper
FI853708A0 (fi)	1985-09-26	Svaorantaendlig, biologiskt soenderfallande funktionell vaetska.